Abbott Neurostim Device Gains FDA Expanded MRI Labelling

Image credit: Abbott

Good news for health giant Abbott to kick off the new year, with its neurostimulation device recently receiving expanded magnetic resonance imaging (MRI) labelling from the US Food and Drug Administration (FDA).

Its Proclaim DRG neurostimulation system enables full-body MRI scans for patients implanted with the device, providing relief from types of complex regional pain syndrome (CRPS) in the lower limbs.

The system works by stimulating dorsal root ganglion (DRG) – clusters of neurons within the spine – and is currently the only FDA-approved DRG technology.

MRIs are commonly used for treating people living with chronic pain, and can help track the progression of conditions such as CRPS.

Trials of the Proclaim DRG device found four out of five people who received the therapy reported significant pain relief and improved quality of life, Abbott said.

Expanded labelling from the FDA will enable its use in full-body scans, for both new and existing patients.

“As we continue to work holistically across chronic pain care, we’re excited to see this new MRI expanded indication for our proprietary and unique Dorsal Root Ganglion Stimulation therapy become another valuable tool in the hands of treating physicians helping people get back to living a life on their terms,” said Abbott Neuromodulation Division President, Pedro Malha.

Check out the full press release from Abbott for further details.